Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 26.2 %

Shares of EGRX opened at $1.30 on Thursday. Eagle Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $6.37. The business has a 50-day simple moving average of $0.93 and a two-hundred day simple moving average of $1.48.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of institutional investors have recently made changes to their positions in EGRX. Jane Street Group LLC bought a new stake in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $96,000. DGS Capital Management LLC grew its position in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $453,000. Finally, RBF Capital LLC grew its position in shares of Eagle Pharmaceuticals by 11.7% in the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares during the last quarter. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.